Anales de la RANM

166 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 METASTATIC COLORECTAL CANCER Eduardo Díaz-Rubio An RANM · Año 2018 · número 135 (02) · páginas 160 a 168 1. AdamR,DeGramont,FiguerasJetal.-Theoncosurgery approach to managing liver metastasis from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012; 17: 1225-1239. 2. Van Cutsem E; Cervantes A; Adam R et al.- ESMO consensus guidelines for the management of patients with metastatic colorectal cáncer. Ann Oncol 2016: 27 (8): 1386-1422. 3. Clinical Practice Guidelines in Oncology (NCCN Guidelines). ColonCancer. Version 1. 2018. www.nccn.org 4. Van Rooijen KL, Shi Q, Goey KKH et al.- Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. Eur J Cancer 2018, 91: 99-106. 5. Petrelli F, Tomasello G, Borgonovo K et al.- Prognostic survival associated with left-sided vs rigth-sided colon cancer: A systematic review and meta-analysis. Jama Oncol 2017, 3: 211-219. 6. Holch JW, Ricard I, Stintzing S, Modest DP and Heineman V.- The relevance of primary tumour location in patients with metastatic colorectal cancer: Ameta-analysis of first-line clinical trials. Eur J Cancer 2016; 70: 87-98. 7. Moretto R, Cremolini C, Rossini D et al.- Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. Oncologist 2016; 21: 988-994. 8. Tejpar S, Stinzing S, Ciardello F et al.- Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer. Retrospective analyses of the CRYSTAL and FIRE-3 trials. Jama Oncol 2017; 3(2):194-201. 9. Salem M, Yin Y, Renfro LA et al.- Rectal versus left- sided colon cancers: clinicopathological differences observed in a pooled analysis of 4.182 patients enrolled to 8 clinical trials from the ARCAD database. J Clin Oncol 2017, 35, no 4, suppl, 675. 10. Taieb J, Rivera F, Siena S et al.- Exploratory analyses assesing the impact of early tumour shrinkage and depth of response on survival outcomes inpatientswith RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. J Cancer Res Clin Oncol 2018, 144: 321-335. 11. Douillard JY, Siena S, Peeters M et al.- Impact of early tumour shrinkage and resection outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer 2015; 51: 1231-1242. 12. Heinemann V, Rivera F, O´Neil BH et al.- A study-level meta-analysis of efficacy data fromhead-to head first-line trials of epidermal growth factor receptor inhibitors vs bevacizumab in patients with RAS wild-type metastatic colorectal cancer. Eur J Cancer 2016, 67: 11-20. 13. Cremolini C, Loupakis F, Antoniotti C et al.- Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol 2015; 26: 1188-1194. BIBLIOGRAFÍA Figura 3. Algoritmo de tratamiento en el CCRm